retatrutide ly3437943 phase 2 trial obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide — Investigational Triple Agonist

As your body composition changes and metabolic rate shifts during weight loss, your thyroid medication dosing may need adjustment

And like any season, its an opportunity to slow down, care for your body, and trust the process

You are provided with comprehensive aftercare advice appropriate to the treatment you have received and we welcome patients getting in touch if they have any questions regarding their experience and results

If you take other supplements or medications, research potential interactions or consult with a healthcare provider

Starting at $189 per month, PlexusDx compounded semaglutide removes cost barriers to sustained therapy